Amany Aziz1, Khalid Alsabban1, Steven M Shea1, Ari Goldberg1, Gopal Gupta 1, and Joseph H Yacoub1
1Radiology, Loyola University Medical Center, Maywood, IL, United States
Synopsis
~
Retrospective evaluation of
the impact of DWI on PI-RADS scoring of TZ lesions. A blinded radiologist evaluates
lesions based on only the DWI sequence and again only on the T2 TSE sequence,
in separate occurrences, in patients who underwent targeted biopsy. New PI-RADS
scores are given for each of the lesions. The given scores are then correlated
with their corresponding Gleason scores. Of the 55 lesions studied, the DWI
score downgraded four lesions from a higher T2 score. DWI could play a role in
evaluation of TZ lesions, however our
data lacked statistical significance.
Recently, there has been an
increasing role of MRI to non-invasively detect the characteristics of
prostatic lesions. Areas of suspicion can be targeted to
improve the detection rate of clinically significant cancers over standard
biopsy sampling techniques hence, fewer biopsies are preformed1-5.
According
to PI-RADS v2, T2-w sequence primarily determined the final score in TZ
(Transitional zone) lesions with exception of one scenario in which a high DWI
can upgrade and intermediate T2 score of three6. We explore the role
DWI might play in downgrading the PI-RADS score, specifically, if a low or
intermediate DWI score can be used to downgrade a higher T2 score.
The study was a retrospective review of TZ lesions identified on MRI and
subsequently referred to MR-US fusion biopsy. Cases were excluded if they did not
have a targeted biopsy, if the DWI acquisition was different than our standard
(acquisition with b values of 50, 800 and 2000), and if the full study, including
original target ROIs, could not be retrieved from our archives. A radiologist
blinded to the biopsy results and the radiology report was presented with only the
DWI/ADC images of the lesions. The radiologist assigned a DWI PI-RADS score and
created a 3D ROI of the lesion. At a later time, the radiologist was presented
with the T2-weighted turbo spin echo (T2 TSE) images to provide a T2 PI-RADS
score. The PI-RADS scores for each sequence were recorded and were compared with
the targeted biopsy. The final PIRADS v2 score was calculated. A downgraded PI-RADS score was also
calculated by using a DWI score of 3 or less to override a higher T2 score (refer
to Fig 1). We also compared targets with Gleason > 6 versus targets with Gleason ≤6 with respect to average ADC value,
volume and largest dimension using Mann Whitney U test.
78 TZ lesion targets were identified. 55 of 78 TZ lesions met research criteria. 14% (8) had
a summed Gleason score of 7, 86 % (47) had Gleason ≤6 (44 negative, 3 Gleason
6). There was no significant difference,
between these 2 groups in average ADC value (p= 0.10), volume (p= 0.37), and
maximum dimension (p=0.57). The distribution of the lesion among DWI PI-RADS
score of 5, 4, 3, 2 and 1 were 42 %, 38.6%, 8.77%, 7.01%, and 0%. The percent of lesions with Gleason of ≥7 in
each of those scores were 20.83% (5/24), 9.09% (2/22), 20% (1/5), and 0% (0/4).
A total of 9 targets had an intermediate to low DWI score (defined as ≤3) four of
which had a higher T2 score and were downgraded using our suggested downgrading
scheme. All four downgraded lesions had
negative Gleason.
In
clinical practice TZ lesions are overcalled with low yield of targeted biopsy
reflecting a high false positive rate.
Lesions of low DWI PI-RADS score are less commonly called. If we use
intermediate or low DWI score to downgrade the PI-RADS score, we can downgrade
the score of few negative targets without downgrading any of the positive
targets. Due to the small number of
positive targets as well as the small number of lesion with low or intermediate
DWI score these data lacked statistical significance.
Acknowledgements
No acknowledgement found.References
[1]. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, HeijminkSW, Hoskin P, Kirkham AP, Padhani AR, Persad R, Puech P, Punwani S, Sohaib A,Tombal B, Villers A, Emberton M. Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging. 2013 Jan;37(1):48-58. doi:10.1002/jmri.23689. Epub 2012 May 7. Review. PubMed PMID: 22566285.
[2].
Franiel T, Stephan C, Erbersdobler A, et al. Areas suspicious for prostate
cancer: MR-guided biopsy in patients with at least one transrectal US-guided
biopsy with a negative finding — multiparametric MR imaging for detection and
biopsy planning. Radiology 2011;259:162–172.
[3]. Roethke M, Anastasiadis AG, Lichy M, Werner
M, Wagner P, Kruck S, Claussen CD, Stenzl A, Schlemmer HP, Schilling D. MRI-guided
prostate biopsy detects clinically significant cancer: analysis of a cohort of
100 patients after previous negative TRUS biopsy. World J Urol. 2012
Apr;30(2):213-8. doi:10.1007/s00345-011-0675-2. Epub 2011 Apr 22. PubMed PMID:
21512807.
[4]. Sciarra A, Panebianco V, Ciccariello M,
et al. Value of magnetic resonance spectroscopy imaging and dynamic
contrast-enhanced imaging for detecting prostate cancer foci in men with prior
negative biopsy. Clin Cancer Res 2010;16:1875–1883
[5]. Haffner
J, Lemaitre L, Puech P, et al. Role of magnetic resonance imaging before
initial biopsy: comparison of magnetic resonance imaging-targeted and
systematic biopsy for significant prostate cancer detection. BJU Int
2011:108:E171–178.
[6]. American College of Radiology. MR Prostate Imaging
Reporting and Data System version 2.0. Accessed 09/2015, from http://www.acr.org/Quality-Safety/Resources/PIRADS/.